KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Other financing activities (2016 - 2025)

Eli Lilly (LLY) has disclosed Other financing activities for 15 consecutive years, with -$25.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities rose 45.32% year-over-year to -$25.1 million, compared with a TTM value of -$772.0 million through Dec 2025, down 57.23%, and an annual FY2025 reading of -$772.0 million, down 57.23% over the prior year.
  • Other financing activities was -$25.1 million for Q4 2025 at Eli Lilly, up from -$30.2 million in the prior quarter.
  • Across five years, Other financing activities topped out at -$500000.0 in Q3 2021 and bottomed at -$686.3 million in Q1 2025.
  • Average Other financing activities over 5 years is -$110.1 million, with a median of -$27.6 million recorded in 2025.
  • The sharpest move saw Other financing activities surged 98.55% in 2021, then tumbled 2183.33% in 2022.
  • Year by year, Other financing activities stood at -$600000.0 in 2021, then crashed by 2183.33% to -$13.7 million in 2022, then plummeted by 130.66% to -$31.6 million in 2023, then crashed by 45.25% to -$45.9 million in 2024, then surged by 45.32% to -$25.1 million in 2025.
  • Business Quant data shows Other financing activities for LLY at -$25.1 million in Q4 2025, -$30.2 million in Q3 2025, and -$30.4 million in Q2 2025.